295 related articles for article (PubMed ID: 29208079)
1. Asthma control, lung function, symptoms, and corticosteroid sparing after omalizumab initiation in patients with allergic asthma.
Pilon D; Kavati A; Ortiz B; Paknis B; Vegesna A; Schiffman B; Zhdanava M; Lefebvre P; Stone B
Allergy Asthma Proc; 2018 Mar; 39(2):127-135. PubMed ID: 29208079
[TBL] [Abstract][Full Text] [Related]
2. Omalizumab for asthma in adults and children.
Normansell R; Walker S; Milan SJ; Walters EH; Nair P
Cochrane Database Syst Rev; 2014 Jan; 2014(1):CD003559. PubMed ID: 24414989
[TBL] [Abstract][Full Text] [Related]
3. Impact of omalizumab on treatment of severe allergic asthma in UK clinical practice: a UK multicentre observational study (the APEX II study).
Niven RM; Saralaya D; Chaudhuri R; Masoli M; Clifton I; Mansur AH; Hacking V; McLain-Smith S; Menzies-Gow A
BMJ Open; 2016 Aug; 6(8):e011857. PubMed ID: 27507234
[TBL] [Abstract][Full Text] [Related]
4. Retrospective Study on the Association of Biomarkers With Real-world Outcomes of Omalizumab-treated Patients With Allergic Asthma.
Kavati A; Zhdanava M; Ortiz B; Lecocq J; Schiffman B; Pilon D; Ho H; Lefebvre P; Stone B
Clin Ther; 2019 Oct; 41(10):1956-1971. PubMed ID: 31563391
[TBL] [Abstract][Full Text] [Related]
5. Longterm clinical outcomes of omalizumab therapy in severe allergic asthma: Study of efficacy and safety.
Mansur AH; Srivastava S; Mitchell V; Sullivan J; Kasujee I
Respir Med; 2017 Mar; 124():36-43. PubMed ID: 28284319
[TBL] [Abstract][Full Text] [Related]
6. Omalizumab: an update on efficacy and safety in moderate-to-severe allergic asthma.
Chipps BE; Figliomeni M; Spector S
Allergy Asthma Proc; 2012; 33(5):377-85. PubMed ID: 23026179
[TBL] [Abstract][Full Text] [Related]
7. Omalizumab decreases exacerbation frequency, oral intake of corticosteroids and peripheral blood eosinophils in atopic patients with uncontrolled asthma.
Pelaia G; Gallelli L; Romeo P; Renda T; Busceti MT; Proietto A; Grembiale RD; Marsico SA; Maselli R; Vatrella A
Int J Clin Pharmacol Ther; 2011 Dec; 49(12):713-21. PubMed ID: 22122813
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study.
Niven R; Chung KF; Panahloo Z; Blogg M; Ayre G
Respir Med; 2008 Oct; 102(10):1371-8. PubMed ID: 18657960
[TBL] [Abstract][Full Text] [Related]
9. Long-term omalizumab treatment in severe allergic asthma: the South-Eastern Mediterranean "real-life" experience.
Tzortzaki EG; Georgiou A; Kampas D; Lemessios M; Markatos M; Adamidi T; Samara K; Skoula G; Damianaki A; Schiza S; Tzanakis N; Siafakas NM
Pulm Pharmacol Ther; 2012 Feb; 25(1):77-82. PubMed ID: 22155001
[TBL] [Abstract][Full Text] [Related]
10. Impact of omalizumab on emergency-department visits, hospitalizations, and corticosteroid use among patients with uncontrolled asthma.
Lafeuille MH; Dean J; Zhang J; Duh MS; Gorsh B; Lefebvre P
Ann Allergy Asthma Immunol; 2012 Jul; 109(1):59-64. PubMed ID: 22727159
[TBL] [Abstract][Full Text] [Related]
11. Oral corticosteroid sparing with omalizumab in severe allergic (IgE-mediated) asthma patients.
Siergiejko Z; Świebocka E; Smith N; Peckitt C; Leo J; Peachey G; Maykut R
Curr Med Res Opin; 2011 Nov; 27(11):2223-8. PubMed ID: 21933100
[TBL] [Abstract][Full Text] [Related]
12. Effect of omalizumab as add-on therapy on asthma-related quality of life in severe allergic asthma: a Brazilian study (QUALITX).
Rubin AS; Souza-Machado A; Andradre-Lima M; Ferreira F; Honda A; Matozo TM;
J Asthma; 2012 Apr; 49(3):288-93. PubMed ID: 22356355
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of omalizumab in severe allergic asthma: a retrospective UK real-world study.
Barnes N; Menzies-Gow A; Mansur AH; Spencer D; Percival F; Radwan A; Niven R
J Asthma; 2013 Jun; 50(5):529-36. PubMed ID: 23574000
[TBL] [Abstract][Full Text] [Related]
14. [Preliminary clinical observation of omalizumab therapy for moderate to severe asthma].
Wu PH; Dong C; Xie JX; Zhang XX; Liu J; Ouyang M; Ma JJ; Huang WH; Ou CX; Li J; Zhang QL
Zhonghua Jie He He Hu Xi Za Zhi; 2021 Jul; 44(7):611-618. PubMed ID: 34256447
[No Abstract] [Full Text] [Related]
15. Effectiveness and safety of omalizumab in severe, persistent IgE-mediated asthma in pediatric and adult patients: a real-world observational study in Egyptian population.
Tarraf HN; Masoud HH; Zidan M; Wahba B
J Asthma; 2020 Feb; 57(2):160-166. PubMed ID: 30592242
[No Abstract] [Full Text] [Related]
16. Real-World Effectiveness of Omalizumab in Severe Allergic Asthma: A Meta-Analysis of Observational Studies.
Bousquet J; Humbert M; Gibson PG; Kostikas K; Jaumont X; Pfister P; Nissen F
J Allergy Clin Immunol Pract; 2021 Jul; 9(7):2702-2714. PubMed ID: 33486142
[TBL] [Abstract][Full Text] [Related]
17. Omalizumab in patients with eosinophilic granulomatosis with polyangiitis: a 36-month follow-up study.
Detoraki A; Di Capua L; Varricchi G; Genovese A; Marone G; Spadaro G
J Asthma; 2016; 53(2):201-6. PubMed ID: 26377630
[TBL] [Abstract][Full Text] [Related]
18. Cost-Effectiveness of Bronchial Thermoplasty, Omalizumab, and Standard Therapy for Moderate-to-Severe Allergic Asthma.
Zafari Z; Sadatsafavi M; Marra CA; Chen W; FitzGerald JM
PLoS One; 2016; 11(1):e0146003. PubMed ID: 26751790
[TBL] [Abstract][Full Text] [Related]
19. Add-on omalizumab in children with severe allergic asthma: a 1-year real life survey.
Deschildre A; Marguet C; Salleron J; Pin I; Rittié JL; Derelle J; Taam RA; Fayon M; Brouard J; Dubus JC; Siret D; Weiss L; Pouessel G; Beghin L; Just J
Eur Respir J; 2013 Nov; 42(5):1224-33. PubMed ID: 23520319
[TBL] [Abstract][Full Text] [Related]
20. Clinical and economic impact of a one-year treatment with omalizumab in patients with severe allergic asthma within a drug programme in Poland.
Jahnz-Różyk K; Lis J; Warchoł M; Kucharczyk A
BMC Pulm Med; 2018 Mar; 18(1):48. PubMed ID: 29548318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
